Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

2017 ◽  
Vol 27 (5) ◽  
pp. 440-444 ◽  
Author(s):  
Seyed-Ali Mostafavi ◽  
Mahmoud Solhi ◽  
Mohammad-Reza Mohammadi ◽  
Shahin Akhondzadeh
Keyword(s):  
Bipolar Disorder ◽  
Weight Gain ◽  
Atypical Antipsychotic ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

Double-Blind, Placebo-Controlled Trial of Divalproex Monotherapy in the Treatment of Symptomatic Youth at High Risk for Developing Bipolar Disorder

2007 ◽  
Vol 68 (05) ◽  
pp. 781-788 ◽  
Author(s):  
Robert L. Findling ◽  
Thomas W. Frazier ◽  
Eric A. Youngstrom ◽  
Nora K. McNamara ◽  
Robert J. Stansbrey ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
High Risk ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

Lithium vs valproate in the maintenance treatment of bipolar I disorder: A post- hoc analysis of a randomized double-blind placebo-controlled trial

2019 ◽  
Vol 54 (3) ◽  
pp. 298-307
Author(s):  
Mehar G Kang ◽  
Hong Qian ◽  
Kamyar Keramatian ◽  
Trisha Chakrabarty ◽  
Gayatri Saraf ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Atypical Antipsychotic ◽  
Maintenance Treatment ◽  
Atypical Antipsychotics ◽  
Controlled Trial ◽  
Hazard Ratio ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Post Hoc Analysis ◽  
Post Hoc

Objective: Lithium and valproate are commonly used either in monotherapy or in combination with atypical antipsychotics in maintenance treatment of bipolar I disorder; however, their comparative efficacy is not well understood. This study aimed to compare the efficacy of valproate and lithium on mood stability either in monotherapy or in combination with atypical antipsychotics. Methods: We performed a post hoc analysis using data from a 52-week randomized double-blind, placebo-controlled trial, that recruited 159 patients with recently remitted mania during treatment with lithium or valproate and adjunctive atypical antipsychotic therapy. Patients were randomized to discontinue adjunctive atypical antipsychotic at 0, 24 or 52 weeks. Results: No significant differences in efficacy were observed between valproate and lithium (hazard ratio: 0.99; 95% confidence interval: [0.66, 1.48]) in time to any mood event. Valproate with 24 weeks of atypical antipsychotic was significantly superior to valproate monotherapy in preventing any mood relapse (hazard ratio: 0.46; 95% confidence interval: [0.22, 0.97]) while lithium with 24 weeks of atypical antipsychotic was superior to lithium monotherapy in preventing mania (hazard ratio: 0.27; 95% confidence interval: [0.09, 0.85]) but not depression. Conclusion: Overall, this study did not find significant differences in efficacy between the two mood-stabilizing agents when used as monotherapy or in combination with atypical antipsychotics. However, study design and small sample size might have precluded from detecting an effect if true difference in efficacy existed. Further head-to-head investigations with stratified designs are needed to evaluate maintenance therapies.

scholarly journals A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in Patients with Bipolar Disorder, Mixed or Depressed Phase, and Alcohol Dependence

2014 ◽  
Vol 38 (7) ◽  
pp. 2113-2118 ◽  
Author(s):  
E. Sherwood Brown ◽  
Domingo Davila ◽  
Alyson Nakamura ◽  
Thomas J. Carmody ◽  
A. John Rush ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Alcohol Dependence ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Metformin for Prevention of Weight Gain and Insulin Resistance with Olanzapine: A Double-Blind Placebo-Controlled Trial

2006 ◽  
Vol 51 (3) ◽  
pp. 192-196 ◽  
Author(s):  
Trino Baptista ◽  
Jessan Martínez ◽  
Anny Lacruz ◽  
Nairy Rangel ◽  
Serge Beaulieu ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Weight Gain ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document